Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Drevs

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholineP Kaufmann-Kolle, J Drevs, M R Berger, et al.
Angiogenesis|March 26, 2004
Angiogenesis and the ET-1/ETA receptor system: immunohistochemical expression analysis in bone metastases from patients with different primary tumorsM Medinger, C P Adler, C Schmidt-Gersbach, et al.
The British Journal of Ophthalmology|April 15, 2008
VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurityC Pieh, H Agostini, C Buschbeck, et al.
Angiogenesis|May 12, 2005
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinomaJ Drevs, M A Konerding, T Wolloscheck, et al.
International Journal of Oncology|December 15, 2010
Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma modelM Medinger, N Esser, J Soltau, et al.
Cancer Research|September 15, 2000
Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma modelJ Drevs, I Hofmann, H Hugenschmidt, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2003
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumoursF A L M Eskens, H Dumez, R Hoekstra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2005
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trialsJ Drevs, U Zirrgiebel, C I M Schmidt-Gersbach, et al.
Cancer Research|April 29, 2000
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administrationJ M Wood, G Bold, E Buchdunger, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholineP Kaufmann-Kolle, J Drevs, M R Berger, et al.
Angiogenesis|March 26, 2004
Angiogenesis and the ET-1/ETA receptor system: immunohistochemical expression analysis in bone metastases from patients with different primary tumorsM Medinger, C P Adler, C Schmidt-Gersbach, et al.
The British Journal of Ophthalmology|April 15, 2008
VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurityC Pieh, H Agostini, C Buschbeck, et al.
Angiogenesis|May 12, 2005
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinomaJ Drevs, M A Konerding, T Wolloscheck, et al.
International Journal of Oncology|December 15, 2010
Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma modelM Medinger, N Esser, J Soltau, et al.
Cancer Research|September 15, 2000
Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma modelJ Drevs, I Hofmann, H Hugenschmidt, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2003
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumoursF A L M Eskens, H Dumez, R Hoekstra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2005
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trialsJ Drevs, U Zirrgiebel, C I M Schmidt-Gersbach, et al.
Cancer Research|April 29, 2000
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administrationJ M Wood, G Bold, E Buchdunger, et al.
Pageof 2